The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000955314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
26/06/2026
Date registered
Help: Date registered
4/08/2026
Date last updated
Help: Date last updated
4/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
4/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Enhancing adherence and self-management in the treatment of respiratory conditions (ENGAGEMENT): a nurse-supported, technology-enabled self-management model of care for health-related quality of life in adults with asthma or chronic obstructive pulmonary disease (COPD)
Scientific title
Enhancing adherence and self-management in the treatment of respiratory conditions (ENGAGEMENT): a randomised controlled trial evaluating a nurse-supported, technology-enabled self-management model of care for improving health-related quality of life (St George's Respiratory Questionnaire) in adults with asthma or chronic obstructive pulmonary disease
Additional trial identifiers [1] 316613 0
None
Universal Trial Number (UTN)
Trial acronym
Enhancing adherence and self-management in the treatment of respiratory conditions (ENGAGEMENT)
Related trial records

Health condition
Health condition(s) studied:
Asthma 339667 0
Chronic Obstructive Pulmonary Disease 339668 0
Condition category
Condition code
Respiratory 335896 335896 0 0
Asthma
Respiratory 335897 335897 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The ENGAGEMENT trial will evaluate a nurse-supported, technology-enabled self-management model of care for adults with asthma or chronic obstructive pulmonary disease (COPD) following a recent acute exacerbation. The intervention comprises an individual face-to-face baseline consultation (up to 90 minutes) with a trained study nurse, personalised education on disease management, medication use, inhaler technique, symptom recognition and self-management, development of an individualised asthma or COPD action plan, and access to the ENGAGEMENT digital health platform. The platform includes symptom monitoring, medication reminders, educational resources, secure messaging with the study nurse, and integration with an electronic inhaler monitoring device and a Bluetooth-enabled peak flow meter (asthma) or micro spirometer (COPD).
Intervention participants will receive individual telehealth follow-up consultations at approximately 2, 6, 12 and 24 weeks after baseline, with each consultation lasting approximately 30 minutes. The nurse-supported component of the intervention is delivered over the first 24 weeks. Participants will continue to have access to the ENGAGEMENT digital health platform, connected monitoring devices, educational resources, symptom monitoring, medication reminders, and secure messaging with the study nurse for the duration of the 18-month study period.
Education will be delivered by the study nurse during the baseline consultation and reinforced during follow-up telehealth consultations and through resources available within the ENGAGEMENT platform. Educational content will be tailored to the participant's respiratory condition, clinical needs and individual goals, and will include inhaler technique, medication use and adherence, recognition and management of worsening symptoms, use of the personalised action plan, self-monitoring of symptoms and lung function, smoking cessation (where appropriate), vaccination recommendations, and other self-management strategies.
The intervention will be delivered by trained study nurses across participating healthcare services. All study nurses will receive standardised training delivered by members of the study team prior to participant recruitment. Training will include delivery of the intervention, participant education, use of the ENGAGEMENT platform and connected devices, telehealth consultation procedures, and study-specific processes to ensure consistent delivery of the intervention across all sites.
Intervention code [1] 332490 0
Treatment: Other
Intervention code [2] 332491 0
Behaviour
Intervention code [3] 333296 0
Treatment: Devices
Description of the comparator or control
Participants randomised to the control group will receive usual care from their existing healthcare providers, consistent with routine clinical practice. Usual care may include follow-up with a general practitioner and/or respiratory specialist, medication management, routine clinical review, and access to standard education and support services as determined by their treating clinicians. Participants will also receive an educational booklet on asthma or chronic obstructive pulmonary disease (COPD) self-management at baseline. They will not receive the ENGAGEMENT intervention, including access to the digital health platform, electronic monitoring devices, a written asthma or COPD action plan, or nurse-led support.
Control group
Active

Outcomes
Primary outcome [1] 343419 0
Change in health-related quality of life measured using the St George's Respiratory Questionnaire (SGRQ) total score
Timepoint [1] 343419 0
6 months from baseline
Secondary outcome [1] 454381 0
Combined number of all-cause hospitalisations and ED visits
Timepoint [1] 454381 0
6, 12 and 18 months from baseline
Secondary outcome [2] 454382 0
Number of all-cause hospitalisations.
Timepoint [2] 454382 0
6, 12 and 18 months from baseline
Secondary outcome [3] 465115 0
Number of all-cause ED visits.
Timepoint [3] 465115 0
6, 12 and 18 months from baseline
Secondary outcome [4] 465116 0
Combined number of respiratory-related hospitalisations and ED visits
Timepoint [4] 465116 0
6, 12 and 18 months from baseline
Secondary outcome [5] 465117 0
Number of respiratory-related hospitalisations.
Timepoint [5] 465117 0
6, 12 and 18 months from baseline
Secondary outcome [6] 465118 0
Number of respiratory-related ED visits.
Timepoint [6] 465118 0
6, 12 and 18 months from baseline
Secondary outcome [7] 465119 0
Time to first event (hospitalisation, first ED visit, or death, whichever comes first). This will be assessed as a composite outcome.
Timepoint [7] 465119 0
Up to 18 months from baseline
Secondary outcome [8] 465120 0
Number of unplanned GP visits
Timepoint [8] 465120 0
6, 12 and 18 months from baseline
Secondary outcome [9] 465121 0
Changes in St George's Respiratory Questionnaire (SGRQ) score
Timepoint [9] 465121 0
12 and 18 months from baseline
Secondary outcome [10] 465123 0
Self-reported minor exacerbations.
Timepoint [10] 465123 0
6, 12 and 18 months from baseline
Secondary outcome [11] 465124 0
Reliever use
Timepoint [11] 465124 0
6, 12 and 18 months from baseline
Secondary outcome [12] 465125 0
Changes in the revised 12-item Partners in Health scale for measuring chronic disease self-management.
Timepoint [12] 465125 0
6, 12 and 18 months from baseline
Secondary outcome [13] 465126 0
Unified Theory of Acceptance and Use of Technology user acceptance questionnaire.
Timepoint [13] 465126 0
Baseline, 12 and 18 months
Secondary outcome [14] 465129 0
Performance of the ENGAGEMENT clinical algorithms (sensitivity and specificity).
Timepoint [14] 465129 0
6, 12 and 18 months from baseline
Secondary outcome [15] 465551 0
Changes in peak expiratory flow rate (PEFR) in participants with asthma
Timepoint [15] 465551 0
6, 12 and 18 months from baseline.
Secondary outcome [16] 465552 0
Changes in forced expiratory volume in 1 second (FEV1) in participants with chronic obstructive pulmonary disease (COPD)
Timepoint [16] 465552 0
6, 12 and 18 months from baseline
Secondary outcome [17] 465553 0
Changes in forced expiratory volume in 6 seconds (FEV6) in participants with chronic obstructive pulmonary disease (COPD)
Timepoint [17] 465553 0
6, 12 and 18 months from baseline

Eligibility
Key inclusion criteria
Adults aged 18 years or older with asthma or chronic obstructive pulmonary disease (COPD) who have experienced a recent moderate-to-severe acute exacerbation requiring a short course of oral corticosteroids with or without antibiotics initiated in hospital or general practice, and/or have had an unplanned general practice visit, emergency department presentation, or hospital admission for their respiratory condition within the past 12 months. Participants must own a smartphone and be able to provide informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants will be excluded if they are unable to provide informed consent (e.g. due to cognitive impairment), are unable to communicate in English, have difficulty following the intervention, are unwilling to engage with the digital aspects of the intervention, have a terminal illness (anticipated survival <12 months), have symptoms suggestive of unstable heart disease, or have contraindications to spirometry according to standard guidelines.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation via the REDCap randomisation module using a computer-generated allocation sequence. Treatment allocation is concealed until participant eligibility is confirmed and baseline assessments are completed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomised to the ENGAGEMENT intervention or usual care using a computer-generated randomisation schedule, stratified by site and diagnosis (asthma or COPD), with randomly permuted block sizes of 2 and 4.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29174 0
The Alfred - Melbourne
Recruitment hospital [2] 29175 0
Austin Health - Austin Hospital - Heidelberg
Recruitment hospital [3] 29176 0
Barwon Health - Geelong Hospital campus - Geelong
Recruitment postcode(s) [1] 45490 0
3004 - Melbourne
Recruitment postcode(s) [2] 45491 0
3084 - Heidelberg
Recruitment postcode(s) [3] 45492 0
3220 - Geelong

Funding & Sponsors
Funding source category [1] 320481 0
Government body
Name [1] 320481 0
Department of Health and Aged Care – Medical Research Future Fund (MRFF)
Country [1] 320481 0
Australia
Primary sponsor type
University
Name
Monash University
Address
Country
Australia
Secondary sponsor category [1] 323941 0
None
Name [1] 323941 0
Address [1] 323941 0
Country [1] 323941 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319033 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 319033 0
Ethics committee country [1] 319033 0
Australia
Date submitted for ethics approval [1] 319033 0
13/11/2025
Approval date [1] 319033 0
10/02/2026
Ethics approval number [1] 319033 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 146050 0
A/Prof Johnson George
Address 146050 0
Centre for Medicine Use and Safety Monash Institute of Pharmaceutical Sciences, Monash University 381 Royal Parade Parkville VIC 3052 Australia
Country 146050 0
Australia
Phone 146050 0
+61 3 9903 9178
Fax 146050 0
Email 146050 0
Contact person for public queries
Name 146051 0
A/Prof Johnson George
Address 146051 0
Centre for Medicine Use and Safety Monash Institute of Pharmaceutical Sciences, Monash University 381 Royal Parade Parkville VIC 3052 Australia
Country 146051 0
Australia
Phone 146051 0
+61 3 9903 9178
Fax 146051 0
Email 146051 0
Contact person for scientific queries
Name 146052 0
Dr Adelle Gadowski
Address 146052 0
Centre for Medicine Use and Safety Monash Institute of Pharmaceutical Sciences, Monash University 381 Royal Parade Parkville VIC 3052 Australia
Country 146052 0
Australia
Phone 146052 0
+61 3 9903 9178
Fax 146052 0
Email 146052 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.